source
- Merck signs up to $2.13 billion deal with SciBrunch for preclinical KRAS inhibitor SPR2015Merck announced it has completed a deal with Chinese biotech SciBrunch Therapeutics, paying $400 million upfront for exclusive global rights to develop, manufacture and commercialize SciBrunch’s pr…
- Adicet's off-the-shelf CAR-T shows 50% kidney response in early lupus trialAn early-stage study of Adicet Bio's off-the-shelf gamma-delta CAR-T cell therapy reported encouraging results in patients with lupus nephritis. After a year of follow-up, half of the evaluable pa…